CRISPR Therapeutics (NASDAQ:CRSP) Adds US$359m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 54%
CRISPR Therapeutics (NASDAQ:CRSP) Adds US$359m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 54%
Investing in stocks inevitably means buying into some companies that perform poorly. But long term CRISPR Therapeutics AG (NASDAQ:CRSP) shareholders have had a particularly rough ride in the last three year. So they might be feeling emotional about the 54% share price collapse, in that time. More recently, the share price has dropped a further 9.6% in a month.
股票投資不可避免地意味着購買一些業績表現不佳的公司,但是長揸CRISPR Therapeutics AG(納斯達克:CRSP)的股東在過去三年中經歷了尤爲艱難的時期。因此,他們可能會對這一時期股價下跌54%感到情緒化。近期,股價在一個月內進一步下跌了9.6%。
While the stock has risen 7.9% in the past week but long term shareholders are still in the red, let's see what the fundamentals can tell us.
儘管該股票在過去一週中上漲了7.9%,但是長期持股者仍然虧損,讓我們看看基本面能告訴我們什麼。
Because CRISPR Therapeutics made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
由於CRISPR Therapeutics在最近十二個月裏出現了虧損,我們認爲市場可能更加關注營業收入和營業收入增長,至少目前是如此。一般而言,沒有盈利的公司被期望每年增長營業收入,並且增速很快。這是因爲快速的營業收入增長可以輕鬆推算出盈利,通常是相當大的盈利。
Over the last three years, CRISPR Therapeutics' revenue dropped 47% per year. That means its revenue trend is very weak compared to other loss making companies. With no profits and falling revenue it is no surprise that investors have been dumping the stock, pushing the price down by 16% per year over that time. When revenue is dropping, and losses are still costing, and the share price sinking fast, it's fair to ask if something is remiss. After losing money on a declining business with falling stock price, we always consider whether eager bagholders are still offering us a reasonable exit price.
在過去的三年中,CRISPR Therapeutics的營業收入每年下降了47%。這意味着與其他虧損企業相比,其營收趨勢非常疲軟。由於沒有盈利且營業收入下降,不足爲奇的是,投資者一直在拋售股票,推動股價在這段時間內每年下降16%。當營業收入下降、虧損依然存在,並且股價迅速下跌時,公正地問一句是否出現了問題是必要的。在虧損的業務和下跌的股價上虧損後,我們總是考慮是否仍然有急需換手的買方以合理的價格向我們報價。
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
下面的圖表顯示了收益和營收隨時間的變化情況(通過單擊圖像揭示確切的值)。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240717/0-9753abb12c4c7952ae3572beddfd6006-0-ee7e6e19d401ef5ee89b79220eda421d.png/big)
CRISPR Therapeutics is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. Given we have quite a good number of analyst forecasts, it might be well worth checking out this free chart depicting consensus estimates.
CRISPR Therapeutics是投資者所熟知的公司,許多聰明的分析師試圖預測未來的利潤水平。鑑於我們有相當數量的分析師預測,這個免費的圖表展示了共識預期,值得一看。
A Different Perspective
不同的觀點
Investors in CRISPR Therapeutics had a tough year, with a total loss of 1.3%, against a market gain of about 24%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. On the bright side, long term shareholders have made money, with a gain of 3% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. It's always interesting to track share price performance over the longer term. But to understand CRISPR Therapeutics better, we need to consider many other factors. Even so, be aware that CRISPR Therapeutics is showing 1 warning sign in our investment analysis , you should know about...
CRISPR Therapeutics的投資者度過了艱難的一年,總虧損爲1.3%,而市場則增長了約24%。不過,要記住,即使最好的股票有時也會在一年的時間內表現不如市場。但從亮點來看,長期股東獲得了收益,在半個十年的時間內每年增長了3%。最近的股票拋售可能是一個機會,因此檢查基本數據是否有長期增長趨勢的跡象可能是值得的。長期跟蹤股價表現總是很有趣的。但要更好地理解CRISPR Therapeutics,我們需要考慮許多其他因素。即便如此,請注意我們的投資分析中CRISPR Therapeutics顯示出了一個警示信號,你應該知道……
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).
如果您喜歡與管理層一起購買股票,那麼您可能會喜歡這個公司的免費列表。 (提示:其中許多公司不爲人注意且具有吸引力的估值。)
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。